Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication

Pharmacogenetics and Genomics

Volumn 17, Issue 7, 2007, Pages 519-528

  Greenbaum, Lior ^a   Strous, Rael D ^b,c   Kanyas, Kyra ^a   Merbl, Yifat ^d   Horowitz, Anat ^d   Karni, Osnat ^a   Katz, Elena ^b,c   Kotler, Moshe ^b,c   Olender, Tsviya ^d   Deshpande, Smita N ^e   Lancet, Doron ^d   Ben Asher, Edna ^d   Lerer, Bernard ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

Akathisia; Extrapyramidal symptoms; Parkinsonism; Regulators of G protein signaling; RGS2; Risperidone; Typical antipsychotics

Indexed keywords

CHLORPROMAZINE; CLOTIAPINE; DOPAMINE RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE; RGS2 PROTEIN; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; RGS2 GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; EXTRAPYRAMIDAL TRACTS; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RGS PROTEINS; RISPERIDONE; SCHIZOPHRENIA;

PARKINSONIA;

EID: 34250213254     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32800ffbb4     Document Type: Article

References (48)

1. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11:2517-2530.
2. Malhotra AK. The relevance of pharmacogenetics to schizophrenia. Curr Opin Psychiatry 2003; 16:171-174.
3. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60:1228-1235.
4. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30 (Suppl 1):S101-S107.
5. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65:25-28.
6. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10:79-104.
7. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-122.
8. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473.
9. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25:197-220.
10. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122:261-273.
11. Kehrl JH, Sinnarajah S. RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol 2002; 34:432-438.
12. 2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol 2005; 7:405-411.
13. Ingi T, Krumins AM, Chidiac P, Brothers GM, Chung S, Snow BE, et al. Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. J Neurosci 1998; 18:7178-7188.
14. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54:527-559.
15. Burns ME, Wensel TG. From molecules to behavior: new clues for RGS function in the striatum. Neuron 2003; 38:853-856.
16. Garzon J, Rodriguez-Munoz M, Sanchez-Blazquez P. Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter. Neuropharmacology 2005; 48:853-868.
17. Dong MQ, Chase D, Patikoglou GA, Koelle MR. Multiple RGS proteins alter neural G protein signaling to allow C. elegans to rapidly change behavior when fed. Genes Dev 2000; 14:2003-2014.
18. Grillet N, Dubreuil V, Dufour HD, Brunet JF. Dynamic expression of RGS4 in the developing nervous system and regulation by the neural type-specific transcription factor Phox2b. J Neurosci 2003; 23:10613-10621.
19. Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ, et al. Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A 2000; 97:12272-12277.
20. Yalcin B,Willis-Owen SA, Fullerton J, Meesaq A, Deacon RM, Rawlins JN, et al. Genetic dissection of a behavioral quantitative trait locus shows that Rgs2 modulates anxiety in mice. Nat Genet 2004; 36:1197-1202.
21. Geurts M, Maloteaux JM, Hermans E. Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. Biochem Pharmacol 2003; 66:1163-1170.
22. Taymans JM, Kia HK, Claes R, Cruz C, Leysen J, Langlois X. Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur J Neurosci 2004; 19:2249-2260.
23. Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003; 38:941-952.
24. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, et al. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 2005; 25:2157-2165.
25. Larminie C, Murdock P,Walhin JP, Duckworth M, Blumer KJ, Scheideler MA, et al. Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Res Mol Brain Res 2004; 17:24-34.
26. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002; 11:1373-1380.
27. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, McCreadie RG, et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry 2004; 55:192-195.
28. Sobell JL, Richard C,Wirshing DA, Heston LL. Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians. Am J Med Genet B Neuropsychiatr Genet 2005; 139:23-27.
29. Leygraf A, Hohoff C, Freitag C, Willis-Owen SAG, Krakowitzky P, Fritze J, et al. Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm Published online June 1, 2006. doi 10.1007/s00702-006-0484-8.
30. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM- IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York: New York State Psychiatric Institute, Biometrics Research; 1994.
31. Kay S, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987; 13:261-276.
32. Simpson G, Angus MP. Scale for assessment extrapyramidal side effects. Acta Psychiatr Scand 1970; 212:11-19.
33. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676.
34. Guy W. ECDEU assessment Manual for Psychopharmacology. US department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, Maryland: National Institute of Mental Health; 1976.
35. Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol Published online May 31, 2006. doi:10.1017/S1461145706006651.
36. Little DP, Braun A, Darnhofer-Demar B, Frilling A, Li Y, McIver RT Jr, et al. Detection of RET proto-oncogene codon 634 mutations using mass spectrometry. J Mol Med 1997; 75:745-750.
37. Little DP, Braun A, Darnhofer-Demar B, Koster H. Identification of apolipoprotein E polymorphisms using temperature cycled primer oligo base extension and mass spectrometry. Eur J Clin Chem Clin Biochem 1997; 35:545-548.
38. McCullough RM, Cantor CR, Ding C. High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Nucleic Acids Res 2005; 33:e99.
39. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
40. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003; 64:898-906.
41. Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; 2:CD005237.
42. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005; 187:137-142.
43. Moskvina V, Craddock N, Holmans P, Owen MJ, O'Donovan MC. Effects of differential genotyping error rate on the type I error probability of case-control studies. Hum Hered 2006; 61:55-64.
44. Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI, et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol Chem 2004; 279:21248-21256.
45. Taymans JM, Leysen JE, Langlois X. Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem 2003; 84:1118-1127.
46. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 2004; 16:711-721.
47. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18:340-345.
48. 2+ and phospholipase C activity reveals that RGS 2, 3, and 4 differentially regulate signaling via the Galphaq/11-linked muscarinic M3 receptor. Mol Pharmacol 2004; 66:1453-1464.